- Home
- ZDAI vs BIVI Comparison
ZDAI vs BIVI Comparison
Compare ZDAI & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZDAI
- BIVI
- Stock Information
- Founded
- ZDAI 2022
- BIVI 2013
- Country
- ZDAI Hong Kong
- BIVI United States
- Employees
- ZDAI N/A
- BIVI N/A
- Industry
- ZDAI General Bldg Contractors - Nonresidential Bldgs
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- ZDAI Consumer Discretionary
- BIVI Health Care
- Exchange
- ZDAI Nasdaq
- BIVI Nasdaq
- Market Cap
- ZDAI 14.8M
- BIVI 14.2M
- IPO Year
- ZDAI 2024
- BIVI N/A
- Fundamental
- Price
- ZDAI $0.39
- BIVI $1.44
- Analyst Decision
- ZDAI
- BIVI
- Analyst Count
- ZDAI 0
- BIVI 0
- Target Price
- ZDAI N/A
- BIVI N/A
- AVG Volume (30 Days)
- ZDAI 2.3M
- BIVI 97.4K
- Earning Date
- ZDAI 12-02-2025
- BIVI 11-10-2025
- Dividend Yield
- ZDAI N/A
- BIVI N/A
- EPS Growth
- ZDAI N/A
- BIVI N/A
- EPS
- ZDAI N/A
- BIVI N/A
- Revenue
- ZDAI $19,275,673.00
- BIVI N/A
- Revenue This Year
- ZDAI N/A
- BIVI N/A
- Revenue Next Year
- ZDAI N/A
- BIVI N/A
- P/E Ratio
- ZDAI N/A
- BIVI N/A
- Revenue Growth
- ZDAI 43.16
- BIVI N/A
- 52 Week Low
- ZDAI $0.36
- BIVI $1.37
- 52 Week High
- ZDAI $107.36
- BIVI $38.50
- Technical
- Relative Strength Index (RSI)
- ZDAI 36.90
- BIVI 32.18
- Support Level
- ZDAI $0.45
- BIVI $1.37
- Resistance Level
- ZDAI $0.40
- BIVI $1.56
- Average True Range (ATR)
- ZDAI 0.04
- BIVI 0.11
- MACD
- ZDAI -0.00
- BIVI -0.01
- Stochastic Oscillator
- ZDAI 18.82
- BIVI 8.27
About ZDAI Primega Group Holdings Limited Ordinary Shares
DirectBooking Technology Co Ltd, formerly Primega Group Holdings Ltd is engaged in transportation services. It operates in the Hong Kong construction industry, mainly handling the transportation of materials excavated from construction sites. Its services principally comprise (i) soil and rock transportation services; (ii) diesel oil trading; and (iii) construction works, which mainly include ELS works and bored piling. The company provide services as a subcontractor to other construction contractors in Hong Kong. Maximum revenue is generated from soil and rock transportation services.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.